<DOC>
	<DOCNO>NCT00986843</DOCNO>
	<brief_summary>The main objective study determine maximum tolerate dose ( MTD ) OratecanTM . Eligible subject study patient histologically cytologically confirm malignant solid tumor refractory standard therapy . The irinotecan hydrochloric acid ( HCl ) tablet escalate administer per body surface area ( BSA ) . The dose HM30181A 60 mg fix . The Route administration irinitecan HM30181A oral . Each cycle consist 21 day . Drugs administer daily 10 consecutive day ( D1 , 2 , 3 , 4 , 5 , 8 , 9 , 10 , 11 12 ) follow washout 9 day .</brief_summary>
	<brief_title>Clinical Trial Evaluate Safety Tolerability OratecanTM Patients With Advanced Solid Malignancies ( Oratecan-102 )</brief_title>
	<detailed_description>Besides main objective , 3 objective follow . 1 . To determine dose-limiting toxicity ( DLT ) OratecanTM 2 . To characterize pharmacokinetics HM30181A , irinotecan metabolite ( SN-38 SN-38G ) follow oral administration OratecanTM 3 . To evaluate anticancer activity OratecanTM patient advance solid malignancy Groups 3 patient per cohort dose level treat escalate dos irinotecan combination fix 60mg dose HM30181A . If 0/3 patient dose level experience DLT , dose irinotecan escalate 10 mg/m2 next dose level . If 1/3 patient dose level experience DLT , cohort expand 3 additional patient 6 patient . If additional patient develop DLT , dose irinotecan escalate next cohort 3 patient . If 2/3 2/6 patient develop DLT , dose escalation cease , previous dose declare MTD .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid tumor Patients experience progressive disease despite conventional anticancer therapy . Patients expect effective treatment prolong survival conventional anticancer therapy Previous chemotherapy ( exclude irinotecan ) , radiotherapy surgical operation allow discontinue least 4 week prior D0 adverse event resolve ( 6 week nitrosoureas mitomycin ) Aged ≥18 Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 A life expectancy great 12 week Adequate bone marrow ( platelet≥100 x 109/L , hemoglobin≥10.0g/dl ANC≥ 1.5 x 109/L , renal ( Creatinine≤1.5mg/dl ) liver function ( AST/ALT/ALP ≤ 3 x upper limit normal total bilirubin≤2mg/dl ) abnormal heart lung function However , AST/ALT/ALP ≤ 5 x upper limit normal patient liver metastasis ALP level ≤ 5 x upper limit normal patient bone metastases allow . Patients need radiotherapy ( except true oncologic emergency occur entry study [ e.g . acute spinal cord compression ] , anticancer drug immunotherapy trial Subjects must provide write informed consent prior performance study specific procedure assessment , must willing comply treatment follow assessment procedures Patients hematopoietic malignancy ( include leukemia , lymphoma , multiple myeloma , myelodysplastic syndrome , myeloproliferative disorder ) , ileus , CNS metastasis , active infection require parenteral systemic antibacterial , antiviral , antifungal therapy . Patients infection may participate clinical trial complete recovery control infection Patients chronic malabsorption , undergone total colectomy Patients undergone hematopoietic stem cell transplantation ( HSCT ) candidate plan HSCT History congestive heart failure , atrial arrhythmia ventricular arrhythmia require medication ; Patients treatment myocardial infarction acute coronary syndrome event within past 6 month . Subjects , investigator 's opinion , treat per protocol due functional impairment due severe comorbid medical condition Pregnant breastfeeding patient ; Women childbearing potential without adequate contraception ( Men must use adequate contraception . ) Subjects intention follow requirement protocol followup management . Subjects follow regularly due psychological , social , family , logistic , geographical reason . Subjects treat PGP inhibitor ( cyclosporine A verapamil ) , contraindicated medication , washout period 2 week . Subjects administer investigational product within 28 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>HM30181A</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>MTD</keyword>
	<keyword>DLT</keyword>
</DOC>